Moderna starts human trial for multi-strain mRNA flu vaccine

In a human study to test an mRNA vaccine targeting multiple influenza strains, the US biotech firm Moderna dosed its first participants on Wednesday. To evaluate the safety of and strength of immune response to the shot called mRNA-1010, the company will recruit 180 adults from the United States for the Phase 1/2 trial. Also read |Young people more vulnerable to Delta mutations of Covid, experts warn In this trial, Moderna will be using the same messenger ribonucleic (mRNA) technology employed in its COVID-19 flu shot, which has a 90 per cent efficacy rate and could lead to the development of a new generation of better flu vaccines. In a statement, CEO Stephane Bancel said that they expect the seasonal influenza vaccine candidates to play a significant role in future combination respiratory vaccines. Inactivated viruses cultivated in chicken eggs are currently used in the majority of flu vaccines. Also read |'World at a perilous point': COVID-19 death toll crosses 4 million worldwide Strains must be chosen six to nine months before the intended use, and the vaccines' effectiveness is between 40 and 60 per cent. Modernahopes mRNA technology, which provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, can accelerate development and increase scalability. The company hopes that the mRNA technology, which is used to create an immune response by delivering genetic molecules, that contain the code for key cellular components of a pathogen, can accelerate development and increase scalability. Have a look |Covid corruption and scandals that rocked the world It is also possible to deliver several mRNA molecules from different strains at the same time. Flu shot currently being developed will target four World Health Organization (WHO) recommended strains of influenza: A(H1N1), A(H3N2), B/Yamagata and B/Victoria. The WHOestimates there are approximately three to five million severe cases of flu each year globally and 290,000 to 650,000 flu-related respiratory deaths. Globally, the WHO reports around three to five million severe cases of flu per year and290,000 to 650,000 deaths due to flu-related respiratory problems. Modernais also considering possible combo vaccines against the flu, SARS-CoV-2, the respiratory syncytial virus (RSV) as well as human metapneumoviruses (hMPV).